{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:52:53Z","timestamp":1788375173911,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug repurposing is one of the modern techniques used in the drug discovery to find out the new targets for existing drugs. Insilico methods have a major role in this approach. We used 60 FDA approved antiviral drugs reported in the last 50\u00a0years to screen against different cancer cell receptors. The thirteen compounds selected after virtual screening are analyzed for their druggability based on ADMET parameters and found the selectivity of guanine derivatives\u2014didanosine, entecavir, acyclovir, valganciclovir, penciclovir, ganciclovir and valacyclovir as suitable candidates. The pharmacophore model, AARR, suggested based on the common feature alignment, shows that the two fused rings as in guanine and two acceptors-one from keto-oxygen (A5) and other from the substituent attached to nitrogen of imidazole ring (A4) give the druggability to the guanine derivatives. The NBO analysis on N9 is indicative of charge distribution from the ring to substituents, which results in delocalization of negative character in most of the ligands. The molecular dynamics simulations also pointed out the importance of guanine scaffold, which stabilizes the ligands inside the binding pocket of the receptor. All these results are indicative of the selectivity of guanine scaffold in anticancer drug development, especially as PARP1 inhibitors in breast, ovarian and prostate cancer. As these seven molecules are already approved by FDA, we can safely go for further preclinical trials.<\/jats:p>","DOI":"10.1038\/s41598-021-95507-4","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T06:03:10Z","timestamp":1628575390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach"],"prefix":"10.1038","volume":"11","author":[{"given":"D. R.","family":"Sherin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. K.","family":"Manojkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"11","key":"95507_CR1","doi-asserted-by":"publisher","first-page":"e0187925","DOI":"10.1371\/journal.pone.0187925","volume":"12","author":"A Rayan","year":"2017","unstructured":"Rayan, A., Raiyn, J. & Falah, M. Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS ONE 12(11), e0187925. https:\/\/doi.org\/10.1371\/journal.pone.0187925 (2017).","journal-title":"PLoS ONE"},{"issue":"9859","key":"95507_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2095\u20132128 (2012).","journal-title":"Lancet"},{"issue":"4","key":"95507_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1051\/bmdcn\/2017070423","volume":"7","author":"CY Huang","year":"2017","unstructured":"Huang, C. Y., Ju, D. T., Chang, C. F., Reddy, P. M. & Velmurugan, B. K. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine 7(4), 23\u201332 (2017).","journal-title":"Biomedicine"},{"issue":"9","key":"95507_CR4","doi-asserted-by":"publisher","first-page":"16852","DOI":"10.3390\/molecules200916852","volume":"20","author":"P Martins","year":"2015","unstructured":"Martins, P. et al. Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine\u2019s tool box. Molecules 20(9), 16852\u201316891 (2015).","journal-title":"Molecules"},{"key":"95507_CR5","unstructured":"Mullin R. Cost to Develop New Pharmaceutical Drug Now Exceeds $25B: A Benchmark Report Estimates that the Cost of Bringing a Drug to Market has More Than Doubled in the Past 10 Years. Chemical & Engineering News on November 24, 2014."},{"key":"95507_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12918-017-0464-7","volume":"11","author":"J Sun","year":"2017","unstructured":"Sun, J. et al. A systematic analysis of FDA-approved anticancer drugs. BMC Syst. Biol. 11, 87 (2017).","journal-title":"BMC Syst. Biol."},{"issue":"3","key":"95507_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","volume":"8","author":"TI Oprea","year":"2011","unstructured":"Oprea, T. I. et al. Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg. 8(3), 61\u201369 (2011).","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"95507_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","volume":"10","author":"WA Chow","year":"2009","unstructured":"Chow, W. A., Jiang, C. & Guan, M. Anti-HIV drugs for cancer therapeutics: Back to the future?. Lancet Oncol 10, 61\u201371 (2009).","journal-title":"Lancet Oncol"},{"key":"95507_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","volume":"175","author":"Y Cha","year":"2018","unstructured":"Cha, Y. et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 175, 168\u2013180 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"95507_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41598-018-37290-3","volume":"9","author":"JA Marrugal-Lorenzo","year":"2019","unstructured":"Marrugal-Lorenzo, J. A., Serna-Gallego, A., Berastegui-Cabrera, J., Pach\u00f3n, J. & S\u00e1nchez-C\u00e9spedes, J. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci. Rep. 9, 17 (2019).","journal-title":"Sci. Rep."},{"issue":"4","key":"95507_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.stem.2011.02.003","volume":"8","author":"W Goessling","year":"2011","unstructured":"Goessling, W. et al. Prostaglandin E2 enhances engraftment of human cord blood stem cells and shows long-term safety in preclinical non-human primate transplant models. Cell Stem Cell 8(4), 445\u2013458 (2011).","journal-title":"Cell Stem Cell"},{"key":"95507_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1183\/09031936.00195010","volume":"38","author":"DH Sahoo","year":"2011","unstructured":"Sahoo, D. H. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J. 38, 1145\u20131150 (2011).","journal-title":"Eur. Respir. J."},{"key":"95507_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cmdc.201300555","volume":"9","author":"M Lucio","year":"2014","unstructured":"Lucio, M., Tran, J., Medina-Franco, J. L., Meurice, N. & Muller, M. Toward drug repurposing in epigenetics: Olsalazine as a hypomethylating compound active in a cellular context. ChemMedChem 9, 560\u2013565 (2014).","journal-title":"ChemMedChem"},{"issue":"5","key":"95507_CR14","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3892\/or.2015.3816","volume":"33","author":"D Cruz-Hernandez","year":"2015","unstructured":"Cruz-Hernandez, D. et al. Ribavirin as a tri-targeted antitumor repositioned drug. Oncol. Rep. 33(5), 2384\u20132392 (2015).","journal-title":"Oncol. Rep."},{"key":"95507_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13027-017-0128-7","volume":"12","author":"M Shaimerdenova","year":"2017","unstructured":"Shaimerdenova, M., Karapina, O., Mektepbayeva, D., Alibek, K. & Akilbekoval, D. The effects of antiviral treatment on breast cancer cell line. Infect. Agents Cancer 12, 18 (2017).","journal-title":"Infect. Agents Cancer"},{"key":"95507_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.biopha.2018.11.127","volume":"110","author":"GN Hema","year":"2019","unstructured":"Hema, G. N., Saraswathy, G. R., Manikanta, M. & Mamatha, K. An update on Drug Repurposing: Re-written saga of the drug\u2019s fate. Biomed. Pharmacother. 110, 700\u2013716 (2019).","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"95507_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"DC Erik","year":"2016","unstructured":"Erik, D. C. & Guangdi, L. Approved Antiviral Drugs over the Past 50 Years. Clin. Miicrobiol. 29(3), 695\u2013747 (2016).","journal-title":"Clin. Miicrobiol."},{"key":"95507_CR18","first-page":"3","volume":"12","author":"S Sara","year":"2018","unstructured":"Sara, S., Daniel, A. & Letizia, L. Emerging functions of the EGFR in cancer. Clin. Miicrobiol. 12, 3\u201320 (2018).","journal-title":"Clin. Miicrobiol."},{"issue":"48","key":"95507_CR19","doi-asserted-by":"publisher","first-page":"28965","DOI":"10.18632\/oncotarget.25656","volume":"9","author":"SS Khaznadar","year":"2018","unstructured":"Khaznadar, S. S. et al. EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication. Oncotarget 9(48), 28965\u201328975 (2018).","journal-title":"Oncotarget"},{"key":"95507_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s42047-018-0029-0","volume":"2","author":"AA Hashmi","year":"2019","unstructured":"Hashmi, A. A. et al. Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: Association with clinicopathologic features and prognostic parameters. Surg. Exp. Pathol. 2, 6 (2019).","journal-title":"Surg. Exp. Pathol."},{"key":"95507_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/sj.bjc.6604855","volume":"100","author":"X Wu","year":"2009","unstructured":"Wu, X. et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br. J. Cancer 100, 334\u2013343 (2009).","journal-title":"Br. J. Cancer"},{"key":"95507_CR22","first-page":"18","volume":"2017","author":"S Chatterjee","year":"1978","unstructured":"Chatterjee, S. & Burns, T. F. Targeting heat shock proteins in cancer: A promising therapeutic approach. Int. J. Mol. Sci. 2017, 18 (1978).","journal-title":"Int. J. Mol. Sci."},{"key":"95507_CR23","first-page":"907","volume":"46","author":"Z Solaroval","year":"2015","unstructured":"Solaroval, Z., Moj, J. & Solar, P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies. Int. J. Oncol. 46, 907\u2013926 (2015).","journal-title":"Int. J. Oncol."},{"key":"95507_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","volume":"141","author":"C Neuzillet","year":"2014","unstructured":"Neuzillet, C. et al. MEK in cancer and cancer therapy. Pharmacol. Ther. 141, 160\u2013171 (2014).","journal-title":"Pharmacol. Ther."},{"key":"95507_CR25","first-page":"672","volume":"13","author":"MJ Schiewer","year":"2014","unstructured":"Schiewer, M. J. & Knudsen, K. E. Transcriptional Roles of PARP1 in Cancer. Mol. Cancer Res. 13, 672 (2014).","journal-title":"Mol. Cancer Res."},{"key":"95507_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar, K. S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 17, 48 (2018).","journal-title":"Mol. Cancer"},{"issue":"11","key":"95507_CR27","first-page":"28","volume":"66","author":"D Srinivasan","year":"2006","unstructured":"Srinivasan, D. & Plattner, R. Activation of abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer 66(11), 28 (2006).","journal-title":"Cancer"},{"issue":"2","key":"95507_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","volume":"1","author":"J Wang","year":"2015","unstructured":"Wang, J. & Pendergast, A. M. The emerging role of ABL kinases in solid tumors. Trends Cancer 1(2), 110\u2013123 (2015).","journal-title":"Trends Cancer"},{"key":"95507_CR29","doi-asserted-by":"publisher","first-page":"180002","DOI":"10.1098\/rsob.180002","volume":"8","author":"KJ Campbell","year":"2018","unstructured":"Campbell, K. J. & Tait, W. G. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8, 180002 (2018).","journal-title":"Open Biol."},{"issue":"4","key":"95507_CR30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","volume":"14","author":"A Frenzel","year":"2009","unstructured":"Frenzel, A., Grespi, F., Chmelewskij, W. & Villunger, A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14(4), 584\u2013596 (2009).","journal-title":"Apoptosis"},{"key":"95507_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0171-x","author":"M Dankner","year":"2018","unstructured":"Dankner, M., Rose, A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations. Oncogene https:\/\/doi.org\/10.1038\/s41388-018-0171-x (2018).","journal-title":"Oncogene"},{"issue":"2","key":"95507_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17(2), 93\u2013115 (2017).","journal-title":"Nat. Rev. Cancer"},{"issue":"608","key":"95507_CR33","first-page":"34","volume":"8","author":"F Schettini","year":"2018","unstructured":"Schettini, F. et al. CDK 4\/6 inhibitors as single agent in advanced solid tumors. Front. Oncol. 8(608), 34 (2018).","journal-title":"Front. Oncol."},{"issue":"12","key":"95507_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel, H. L. & Mercurio, A. M. VEGF target the tumour cell. Nat. Rev. Cancer 13(12), 871\u2013882 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"95507_CR35","unstructured":"Glide, Desmond, Schr\u00f6dinger, LLC (2018)."},{"key":"95507_CR36","unstructured":"Maestro, Schr\u00f6dinger, LLC (2018)."},{"key":"95507_CR37","unstructured":"https:\/\/www.chemcraftprog.com."},{"key":"95507_CR38","doi-asserted-by":"publisher","first-page":"99385","DOI":"10.1039\/C6RA19045F","volume":"6","author":"DR Sherin","year":"2016","unstructured":"Sherin, D. R., Manojkumar, T. K. & Rajasekharan, K. N. CRANAD-1 as a cyanide sensor in aqueous media:a theoretical study. RSC Adv. 6, 99385\u201399390 (2016).","journal-title":"RSC Adv."},{"key":"95507_CR39","unstructured":"Jaguar, Schr\u00f6dinger, LLC (2018)."},{"key":"95507_CR40","unstructured":"https:\/\/www.rcsb.org\/structure\/."},{"key":"95507_CR41","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95507-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:20:49Z","timestamp":1670052049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95507-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95507"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95507-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-477400\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16251"}}